PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging

Cancer Research

Volumn 62, Issue 14, 2002, Pages 4015-4022

  Drevs, Joachim ^a   Müller Driver, Ralph ^a   Wittig, Christine ^a   Fuxius, Stefan ^a   Esser, Norbert ^a   Hugenschmidt, Harald ^a   Konerding, Moritz A ^c   Allegrini, Peter R ^d   Wood, Jeanette ^d   Hennig, Jürgen ^b   Unger, Clemens ^a   Marmé, Dieter ^a  

^a TUMOR BIOLOGY CENTER   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GADOTERIC ACID; HOE 33342; PROTEIN TYROSINE KINASE INHIBITOR; SUPERPARAMAGNETIC IRON OXIDE; VASCULOTROPIN INHIBITOR; VATALANIB;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD FLOW VELOCITY; BLOOD VESSEL PERMEABILITY; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HISTOLOGY; KIDNEY CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR BLOOD FLOW;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZIMIDAZOLES; BLOOD VESSELS; CAPILLARY PERMEABILITY; CARCINOMA, RENAL CELL; ENZYME INHIBITORS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; FLUORESCENT DYES; HETEROCYCLIC COMPOUNDS; KIDNEY NEOPLASMS; MAGNETIC RESONANCE ANGIOGRAPHY; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; PHTHALAZINES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; REGIONAL BLOOD FLOW;

EID: 0037099598     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: Pharmacokinetics, clinical outcome and comparison of formulations
2. Monitoring responses to antiangiogenic agents using noninvasive imaging tests
3. MR microcirculation assessment in cervical cancer: Correlation with histomorphological tumor markers and clinical outcome
4. Tumor angiogenesis: Therapeutic implications
5. Phase I dose escalation, pharmacokinetic (pk) study of a novel vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 (PTK/ZK)
6. Pharmacological profile of a novel, potent and orally active inhibitor of VEGF receptor tyrosine kinases
7. Effects of PTK787/ZK 222584, a specific inhibitor of VEGF-receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
8. Inhibition of VEGF receptor tyrosine kinase
9. Antitumor effects of α-interferon and γ-interferon on a murine renal cancer (Renca) in vitro and in vivo
10. Adjuvant immunotherapy of established murine renal cancer by interleukin 2 stimulated cytotoxic lymphocytes
11. Experimental animal models for the study of therapeutic approaches in renal cell carcinoma
12. Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumors
13. Modeling tracer kinetics in dynamic GdDTPA MR imaging
14. Analysis of tracer transit in rat brain after carotid artery and femoral vein administration using linear system theory
15. Regional brain activation by bicuculline visualized by functional magnetic resonance imaging. Time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using intravascular contrast agent
16. NMR imaging of changes in vascular morphology due to tumor angiogenesis
17. A simple and accurate method for 3-D measurements in microcorrosion casts illustrated with tumour vascularization
18. Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional study
19. Pentobarbital-sensitive EDHF comediates ACh-induced arteriolar dilation in the hamster microcirculation
20. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. I. Fundamental concepts
21. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody
22. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis